| Literature DB >> 34538745 |
Valery Likhvantsev1, Giovanni Landoni2, Sergey Perekhodov3, Nikolay Chaus3, Kristina Kadantseva4, Lyubov Ermokhina5, Anastasia Baeva6, Mikhail Yadgarov6, Levan Berikashvili6, Artem Kuzovlev6, Andrey Grechko6.
Abstract
OBJECTIVES: Because there is increasing evidence of serious deterioration in long-term quality of life (QoL) in coronavirus 2019 (COVID-19) intensive care unit (ICU) survivors, the authors identified predictors of poor quality of life in these patients.Entities:
Keywords: COVID-19; Intensive Care; SARS-CoV-2; critical care; low molecular weight heparin; mortality; quality life; quality of life
Mesh:
Year: 2021 PMID: 34538745 PMCID: PMC8401277 DOI: 10.1053/j.jvca.2021.08.036
Source DB: PubMed Journal: J Cardiothorac Vasc Anesth ISSN: 1053-0770 Impact factor: 2.628
Fig 1Flow chart of the study. ICU, intensive care unit.
Frequency of Comorbid Conditions in Patients With Normal/Reduced Physical and Mental Components
| Comorbid Condition | Patients With a Normal Physical Component | Patients With a Reduced Physical Component | p Value | Patients With a Normal Mental Component | Patients With a Reduced Mental Component | p Value |
|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | 3 (7.5%) | 12 (14.1%) | 0.4 | 4 (6.2%) | 11 (18.3%) | 0.053 |
| Cerebrovascular insufficiency | 8 (20.0%) | 30 (35.3%) | 0.1 | 13 (20.0%) | 25 (41.7%) | 0.01 |
| Peripheral arterial disease | 22 (55.0%) | 60 (70.6%) | 0.1 | 43 (66.2%) | 39 (65.0%) | 0.9 |
| Diabetes | 6 (15.0%) | 20 (23.5%) | 0.3 | 12 (18.5%) | 14 (23.3%) | 0.5 |
| Arterial hypertension | 18 (45.0%) | 53 (62.4%) | 0.8 | 37 (56.9%) | 34 (56.7%) | 0.9 |
| Chronic kidney disease | 5 (12.5%) | 19 (22.4%) | 0.2 | 12 (18.5%) | 12 (20.0%) | 0.9 |
| Myocardial infarction | 4 (10.0%) | 19 (22.4%) | 0.1 | 10 (15.4%) | 14 (23.3%) | 0.4 |
| Congestive heart failure | 1 (2.5%) | 4 (4.7%) | 0.9 | 2 (3.1%) | 3 (5.0%) | 0.7 |
| Liver failure | 0 (0.0%) | 3 (3.5%) | 0.6 | 1 (1.5%) | 2 (3.3%) | 0.6 |
| Diabetic organ damage | 6 (15.0%) | 16 (18.8%) | 0.8 | 10 (15.4%) | 12 (20.0%) | 0.6 |
| Peptic ulcer | 2 (5.0%) | 5 (5.9%) | 0.9 | 5 (7.7%) | 2 (3.3%) | 0.4 |
| Hemiplegia | 0 (0.0%) | 4 (4.7%) | 0.3 | 0 (0.0%) | 4 (6.7%) | 0.051 |
| Malignant neoplasms | 1 (2.5%) | 7 (8.2%) | 0.4 | 2 (3.1%) | 3 (5.0%) | 0.7 |
| Charlson comorbidity index | 1 (IQR: 0-3) | 2 (IQR: 1-5) | 0.019 | 2 (IQR: 1-4) | 2 (IQR: 1-5) | 0.5 |
Abbreviations: IQR, interquartile range.
Descriptive Statistics: Patient Characteristics and Prescribed Therapy in Patients With Normal/Reduced Physical and Mental Components
| Parameter | Patients With a Normal Physical Component | Patients With a Reduced Physical Component | p Value | Patients With a Normal Mental Component | Patients With a Reduced Mental Component | p Value |
|---|---|---|---|---|---|---|
| Medical and demographic parameters | ||||||
| Sex, female | 8 (20.0%) | 43 (50.6%) | 0.002 | 27 (41.5%) | 24 (40.0%) | 0.9 |
| Age, y | 50.0 (IQR: 40.3-58.0) | 58.0 (IQR: 51.0-65.5) | <0.001 | 54.0 (IQR: 48.5-62.0) | 57.0 (IQR: 48.0-66.0) | 0.2 |
| Body mass index, kg/m2 | 28.1 (IQR: 25.1-31.8) | 28.0 (IQR: 25.2-36.8) | 0.8 | 29.4 (IQR: 27.0-37.6) | 26.0 (IQR: 24.5-32.5) | 0.013 |
| Mechanical ventilation | 2 (5.0%) | 5 (5.9%) | 0.9 | 3 (4.6%) | 4 (6.7%) | 0.7 |
| Characteristics of the severity of the condition on admission | ||||||
| SOFA, score | 1.0 (IQR: 1.0-2.0) | 1.0 (IQR: 1.0-2.0) | 0.9 | 1.0 (IQR: 1.0-2.0) | 1.5 (IQR: 1.0-2.0) | 0.6 |
| NEWS, score | 7.0 (IQR: 5.0-8.0) | 7.0 (IQR: 5.0-8.0) | 0.7 | 7.0 (IQR: 5.0-9.0) | 7 (IQR: 5.0-8.0) | 0.4 |
| CT, no involvement | 3 (7.5%) | 11 (12.9%) | 0.5 | 5 (7.7%) | 9 (15.0%) | 0.3 |
| CT, 1-25% involvement | 3 (7.5%) | 5 (5.9%) | 0.7 | 6 (9.2%) | 2 (3.3%) | 0.3 |
| CT, 26-49% involvement | 11 (27.5%) | 20 (23.5%) | 0.7 | 18 (27.7%) | 13 (21.7%) | 0.5 |
| CT, 50-75% involvement | 19 (47.5%) | 40 (47.1%) | 0.9 | 30 (46.2%) | 29 (48.3%) | 0.9 |
| CT, 76-100% involvement | 4 (10.0%) | 9 (10.6%) | 0.9 | 6 (9.2%) | 7 (11.7%) | 0.8 |
| Length of stay, d | ||||||
| Intensive care unit stay | 4.5 (IQR: 3.0-7.0) | 5.0 (IQR: 3.0-7.0) | 0.9 | 5.0 (IQR: 3.0-7.0) | 4.0 (IQR: 3.0-7.0) | 0.7 |
| Hospital stay | 16.0 (IQR: 12.3-18.0) | 16.0 (IQR: 12.0-22.5) | 0.7 | 16.0 (IQR: 13.0-19.5) | 17.0 (IQR: 12.0-22.8) | 0.7 |
| Prescribed therapy | ||||||
| Enoxaparin | 29 (72.5%) | 44 (51.8%) | 0.03 | 42 (64.6%) | 31 (51.7%) | 0.2 |
| Unfractionated Heparin | 9 (22.5%) | 27 (31.8%) | 0.4 | 20 (30.8%) | 16 (26.7%) | 0.7 |
| Tocilizumab | 17 (42.5%) | 31 (36.5%) | 0.6 | 26 (40.0%) | 22 (36.7%) | 0.7 |
| Hydroxychloroquine | 28 (70.0%) | 56 (65.9%) | 0.7 | 50 (76.9%) | 34 (56.7%) | 0.022 |
| Antiviral therapy | 14 (35.0%) | 27 (31.8%) | 0.8 | 23 (35.4%) | 18 (30.0%) | 0.6 |
Abbreviations: CT, computed tomography; IQR, interquartile range; NEWS, National Early Warning Score; SOFA, Sequential Organ Failure Assessment.
Fig 2Receiver operating characteristic analysis: quantitative predictors of the physical (A) and mental (B) components of QoL. BMI, body mass index; QoL; quality of life.
Fig 3Predictors of physical and mental components of COVID-19 survivors quality of life at a multivariate analysis. BMI, body mass index; COVID-19, coronavirus 2019; ICU, intensive care unit; OR, odds ratio.